Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Festival of Genomics and Biodata 2026
26 slides from Inovio Pharmaceuticals's conference presentation, Jan 28, 2026
Slide 1: An Advanced Non-Viral Gene Delivery Technology Enables Secretion of FVIII
An Advanced Non-Viral Gene Delivery Technology Enables Secretion of FVIII from Skeletal Muscle Trevor Smith, PhD. Inovio Pharmaceuticals
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 3: Company Overview
Company Overview Groundbreaking Late-Stage DNA Medicines Platform Company FOUNDATION Nasdaq Listed Philadelphia, PA (Headquarters) San Diego, CA (R&D and Device Manufacturing) INO >150 51,000 sq.ft. Employees Fully-Integrated cGMP Manufacturing Site Commercial Ready Customizable in vivo Flexible, Va
Slide 4: INOVIO Pipeline
INOVIO Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION DMAbs INO-5401 VGX-3100 INO-3107 * Various Targets BRCA 1/2 Mutation Anal Dysplasia RRP DPROTs INO-4201 INO-3112 Various targets Ebola Booster Head & Neck Cancer DLNPs INO-6172 INO-5401 Various targets HIV Glioblastoma INO-6160 HIV DMA
Slide 5: Customized In Vivo-Generated Proteins, Long-Lasting Systemic Therapeutic Benefits
Customized In Vivo-Generated Proteins, Long-Lasting Systemic Therapeutic Benefits 1 Determine and select the 2 Bioengineering for 4 Insert sequence for 6 DNA is administered via CELLECTRA device to 7 The protein encoded by protein of interest in vivo expression each selected protein enable local exp
Slide 6: DNA Medicine Platform
DNA Medicine Platform CELLECTRA Delivery enhances uptake of DNA medicine
Slide 7: CELLECTRA Delivery Device Enhances Uptake of DNA Medicine
CELLECTRA® Delivery Device Enhances Uptake of DNA Medicine Track record of success in the clinic: • Nearly 6,000 subjects & 19,000 CELLECTRA 5PSP doses given by both investigational/ commercial-ready CELLECTRA devices • 2 generations: CELLECTRA 2000, followed by CELLECTRA 5PSP developed to support c
Slide 8: INOVIO's Proprietary Platform Technology Permits Enhanced Gene Delivery
INOVIO's Proprietary Platform Technology Permits Enhanced Gene Delivery GFP gene expression in rabbit muscle RFP gene expression in mouse muscle No - EP EP + PBS formulation EP + enhanced formulation With EP Schommer et al. Hum Gene Ther. 2019 Sardesai & Weiner Curr Opin Immunol. 2011 + = Increased
Slide 9: Further Pulse and Fluidic Optimization Leading to Enhanced Expression
Further Pulse and Fluidic Optimization Leading to Enhanced Expression The EP electrical field parameters and injected fluid distribution have been optimized to align to permit enhanced transgene expression in the muscle (shown as GFP reporter gene expression in NZW rabbit muscle)
Slide 10: Utilization of Enhanced Delivery Technology to Develop a DMAb as a Medical Countermeasure
Utilization of Enhanced Delivery Technology to Develop a DMAb as a Medical Countermeasure Human Clinical Data – Proof of Concept
Slide 11: Phase 1 Proof-of-Concept Trial Evaluating DMAbs for COVID-19
Phase 1 Proof-of-Concept Trial Evaluating DMAbs for COVID-19 • Dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of mAb AZD5396 and mAb AZD8076 following EP delivery of optimized pDNA AZD5396 and pDNA AZD8076 • Healthy Volunteer Study • Supported by the Joint Pro
Slide 12: SARS-CoV-2-DMAB01 Clinical Study Design
SARS-CoV-2-DMAB01 Clinical Study Design Dose Total • Phase 1 open-label, single-center, dose escalation Each dMAb Doses Dose Total Combined AZD5396 per Schedule Dose Dose study focusing on safety and PK Cohort n and AZD8076 dMAb (Day, D) per dMAb dMAbs - Design allows for exploration of dose respons
Slide 13: Treatment Administration is Well Tolerated
Treatment Administration is Well Tolerated Number of Subjects with Elicited Local Reactions by Maximum Severity Grade Per Person in the First 7 Days After Last Dose None Mild Moderate Severe Total Pain 2 27 15 0 44 Pruritis 40 4 0 0 44 Erythema 25 16 3 0 44 Swelling 40 3 1 0 44 Scab 4 40 0 0 44 Infe
Slide 14: Minimal Systemic Adverse Events Reported
Minimal Systemic Adverse Events Reported Elicited Adverse Events for the First 10 Days After Final Dose Subja Event Mild Moderate Severe Day 0 Day 3 Day 7 Day 10 Hypotension 1 1 1 0 0 0 0 1 0 Hyperhidrosis 0 0 0 0 0 0 0 0 0 Erythema (systemic) 0 0 0 0 0 0 0 0 0 Headache 3 4 4 0 0 1 2 1 0 Dizziness 0
Slide 15: Phase 1 Trial: Key Takeaways From Data
Phase 1 Trial: Key Takeaways From Data • Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in DURABLE AND CONSISTENT DMAb EXPRESSION all participants reaching that timepoint 1024 Serum Concentration, ng/mL 1 x 0.5 mg • No anti-drug antibodies (ADA): no immune 512 2 x
Slide 16: No Anti-drug Antibodies (ADA) Detected
No Anti-drug Antibodies (ADA) Detected No ADAs were detected in against the expressed DMAbs, AZD5396 or AZD8076 in any of the 39 participants AZD5396 ADA AZD8076 ADA Cohort B: 2 x 0.5 mg Redosing Cohort G: 4 x 0.5 mg Tebas P et al. Nat Med. 2025
Slide 17: mAbs Isolated from Human Serum Displayed Functionality
mAbs Isolated for Human Serum Displayed Functionality DMAbs isolated from participants serum displayed antigen binding and neutralization activity - Isolated DMAbs bound to SARS-CoV-2 Spike RBD antigen - Isolated DMAbs neutralized SARS-CoV-2 pseudoviruses at potency values matching the Evushield par
Slide 18: DMAb/DPROT Technology Has Potential as a New Treatment Paradigm in Rare Disease
DMAb/DPROT Technology Has Potential as a New Treatment Paradigm in Rare Disease • Platform has demonstrated ability for long-term protein secretion - Clinical PoC published in Nature Medicine1 • Safety data supports its future tolerability profile • Highly differentiated from existing platforms - Ab
Slide 19: Advancing DPROT Pre-clinical Candidates - Hemophilia A
Advancing DPROT Pre-clinical Candidates - Hemophilia A
Slide 20: Hemophilia A Overview
Hemophilia A Overview Diagnosis • Inherited X-linked recessive bleeding disorder due to deficiency of Factor VIII (FVIII) • ‘Mild’, ‘moderate’, or ‘severe’ based on FVIII in blood (as % of normal) Epidemiology and disease impact • ~66,000 patients with hemophilia A in the eight major markets (2024)
Slide 21: An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression is Still Needed
An Alternative to Viral-based Delivery for Long-Term In Vivo Protein Expression is Still Needed • Long-term in vivo protein expression remains a sought-after goal for genetic disorders such as Hemophilia • Significant treatment improvements have been made, but hurdles remain - Pre-existing immunity
Slide 22: FVIII DPROT Preclinical Program Overview
FVIII DPROT Preclinical Program Overview Program goal: to identify and characterize a functional FVIII DPROT with enhanced in vivo expression and function. 40 1. Plasmid design & synthesis FVIII activity (%) 30 Iterative 20 FVIII design 10 process 0 Gen. 1 Gen. 2 Gen.3 2. In vivo screening Subsequen
Slide 23: INOVIO DPROT Approach for Hemophilia A: HuFVIII Expressed and Functional in FVIII KO Mice
INOVIO DPROT Approach for Hemophilia A: HuFVIII is Expressed and Functional in FVIII KO Mice HuFVIII Activity 0.7 Activity (mean ± SEM) 0.6 Human FVIII (IU/ml) 0.5 • Demonstrates ectopic expression of huFVIII can be 0.4 achieved in skeletal muscle cells: activity reaching 50% 0.3 • Confirms complex
Slide 24: Inovio DPROT Approach for Hemophilia A: Phenotypic Correction of Bleeding in FVIII KO Mice
Inovio DPROT Approach for Hemophilia A: Phenotypic Correction of Bleeding in FVIII KO Mice Mouse tail clip model • pDNA-treated FVIII knockout mice showed significantly reduced bleeding time and blood loss compared to control (pGX0001-treated) knockout mice. • Bleeding control in pDNA-treated knocko
Slide 25: DMAb/DPROT Technology Has Potential as a New Treatment Paradigm for Hem A and Other Rare Diseases
DMAb/DPROT Technology Has Potential as a New Treatment Paradigm for Hem A and Other Rare Diseases • Platform allows for rapid design, production and testing of new candidates • Facility infrastructure and team background expertise has been applied to multiple DPROT targets with rapid preclinical suc
Slide 26: Thank you.
Thank you. Contact: trevor.smith@inovio.com
Inovio Pharmaceuticals — Festival of Genomics and Biodata 2026 on 6ix